TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04237259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent-administered TCM pediatric massage training
Description: Massage therapy is a kind of complementary and alternative therapy, which involves a number of techniques such as friction, pressing, rubbing, grasping, pinching, and kneading. TCM pediatric massage, also called pediatric tuina and pediatric anmo, is a special part of TCM massage system that usually use lines or surfaces rather than points as acupoints and the manipulations are different from those of TCM adult massage. From TCM perspective, the pathogenesis of ADHD is the abnormal exuberance of yang, which can be relieved by specific approaches of massage.~Participants in this group will receive two TCM pediatric massage training sessions (5 hours in total, one is 3 hours, and the other is 2 hours). The protocol will be tested for feasibility at the first feasibility stage (the first 8 subjects).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation Exercise
Description: The principle of progressive muscle relaxation exercise is to achieve a relaxation state through relaxing our muscles. With training, we become more familiarized with the sense of relaxation so that we can voluntarily induce this sensation in the face of a stressor.
Study: NCT00982020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
Study: NCT04808765

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Breast reconstruction
Description: immediate mastectomy with breast reconstruction with implants or expanders

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Breast reconstruction
Description: immediate mastectomy with breast reconstruction with implants or expanders
Study: NCT01205269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dry powder for inhalation, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dry powder for inhalation, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683, 200 mcg
Description: Dry powder for inhalation, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683, 200 mcg
Description: Dry powder for inhalation, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683, 200 mcg
Description: Dry powder for inhalation, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683, 200 mcg
Description: Dry powder for inhalation, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683, 200 mcg
Description: Dry powder for inhalation, single dose
Study: NCT00982020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard behavioral weight intervention
Description: One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intense behavioral weight intervention
Description: Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
Study: NCT03793101

Intervention type: PROCEDURE
Intervention: BiMICS
Description: Biaxial microincision cataract surgery implies performing of 2 corneal incisions under 1.8mm, removal of the crystalline lens with the use of ultrasounds and implantation of the artificial intraocular lens.

Intervention type: PROCEDURE
Intervention: BiMICS
Description: Biaxial microincision cataract surgery implies performing of 2 corneal incisions under 1.8mm, removal of the crystalline lens with the use of ultrasounds and implantation of the artificial intraocular lens.
Study: NCT04848285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: Additional 2 or more sessions of out-of-bed activity to the standard stroke care, focused in active sitting, standing and walking assisted by physiotherapists

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard protocol of mobilization in acute stroke patients admitted to the Stroke Unit at the discretion of the nursing and physiotherapy staff
Study: NCT04231656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEARSIGHT and NICCOMO measurements in sequence A
Description: Starting from 0° position, shift to position +20°, then tilt to -20°, and finally back to the 0° position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEARSIGHT and NICCOMO measurements in sequence A
Description: Starting from 0° position, shift to position +20°, then tilt to -20°, and finally back to the 0° position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEARSIGHT and NICCOMO measurements in sequence B
Description: Starting from 0° position, shift to position -20°, then tilt to +20°, and finally back to the 0° position and collect the last group of figures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEARSIGHT and NICCOMO measurements in sequence B
Description: Starting from 0° position, shift to position -20°, then tilt to +20°, and finally back to the 0° position and collect the last group of figures.
Study: NCT01444534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dbees; diabetes mobile phone application
Description: Participants randomized to the intervention group (G2) were asked to stop using their paper logbook and start using an electronic logbook on their computer and mobile phone using an application of Dbees. The Dbees software enables the mobile phone to be used as a small computer to record the blood glucose values, dose of insulin injection, daily carbohydrate intake, amount of physical activity, and blood pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
Study: NCT01259713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Description: Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
Study: NCT01786356

Intervention type: DEVICE
Group type: OTHER
Intervention: HOYA iMics Y-60H
Description: same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye

Intervention type: OTHER
Group type: OTHER
Intervention: B&L MI60
Description: same-day bilateral cataract surgery with implantation of intraocular lens B\&L MI60 in one eye
Study: NCT03502343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy
Description: All patients will receive slow (over 30-40 minutes) intravenous administration of nab-paclitaxel (125 mg/m2) on days 1 and 15, and gemcitabine (1000 mg/m2) on days 1, 8, and 15 of a 28- day cycle (every 4 weeks). Treatment will discontinue if disease progression or intolerable toxicity is observed, if the patient withdraws from the study, or at the physician's discretion.~Dose reduction of the chemotherapeutic agent and/or delay of administration is allowed if serious treatment-related AEs occur, according to specified guideline in study protocol (Level 1: 100% -\> 80%; Level 2: 80% -\> 60%). If dose reduction is needed more than Level 2, the patient will be dropped from the trial.
Study: NCT02587325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: nab-sirolimus is an mTOR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: nab-sirolimus is an mTOR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: nab-sirolimus is an mTOR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: nab-sirolimus is an mTOR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: nab-sirolimus is an mTOR inhibitor
Study: NCT03275168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Sexual partners will receive dyadic counseling and support for condom negotiation after receipt of individual evidence based HIV/STI prevention intervention (Sister-to-Sister (female) and Focus on the Future (male).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual evidence-based STI/HIV prevention intervention
Description: Sexual partners will receive individual evidence-based HIV/STI prevention counseling without partner debrief and/or practice negotiating condom use.
Study: NCT02236390

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure, Relaxation, and Rescripting Therapy
Description: 5 sessions that last approximately one hour addressing nightmares and sleep problems. Participants will log sleep events and associated symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure, Relaxation, and Rescripting Therapy
Description: 5 sessions that last approximately one hour addressing nightmares and sleep problems. Participants will log sleep events and associated symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy - Cognitive
Description: 12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy - Cognitive
Description: 12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy - Cognitive
Description: 12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.
Study: NCT03576547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib Hydrochloride
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT01658982

Intervention type: OTHER
Intervention: cardiopulmonary exercise testing
Description: 3 minute step test compared to 6 minute bicycle test
Study: NCT04215120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desidustat Oral Tablet
Description: Desidustat tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Epoetin Injection
Study: NCT02706041

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definitive Closure Laparotomy
Description: Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Damage Control Laparotomy
Description: Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
Study: NCT03593239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco flavored JUUL 1.7% ENDS
Description: Treatment with Tobacco flavored JUUL 1.7% ENDS (10 puffs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco flavored JUUL 5% ENDS
Description: Treatment with Tobacco flavored JUUL 5% ENDS(10 puffs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint flavored JUUL 1.7% ENDS
Description: Treatment with Mint flavored JUUL 1.7% ENDS(10 puffs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint flavored JUUL 5% ENDS
Description: Treatment with Mint flavored JUUL 5% ENDS(10 puffs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit Medley flavored JUUL 1.7% ENDS
Description: Treatment with Fruit Medley flavored JUUL 1.7% ENDS(10 puffs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit Medley flavored JUUL 5% ENDS
Description: Treatment with Fruit Medley flavored JUUL 5% ENDS(10 puffs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crème brulee flavored JUUL 1.7% ENDS
Description: Treatment with Crème brulee flavored JUUL 1.7% ENDS(10 puffs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crème brulee flavored JUUL 5% ENDS
Description: Treatment with Crème brulee flavored JUUL 5% ENDS(10 puffs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 1.7% ENDS 10 puffs vs. ad lib puffs
Description: Treatment with JUUL 1.7% ENDS 10 puffs vs. ad libitum puffs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 5% ENDS 10 puffs vs. ad lib puffs
Description: Treatment with JUUL 5% ENDS 10 puffs vs. ad libitum puffs
Study: NCT02088294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Education (LS)
Description: See arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Education (LS)
Description: See arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Education (LS)
Description: See arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LS + Stress Reduction Guided Imagery
Description: See Arm Description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LS + Activity/Eating Guided Imagery
Description: See arm description
Study: NCT00817778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Subjects will be treated with tolerable dose twice daily for another 24 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be treated with tolerable dose twice daily for another 24 days.
Study: NCT00504127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxcinod 375 mg bid
Description: Naproxcinod 375 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxcinod 750 mg bid
Description: Naproxcinod 750 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500 mg bid
Description: Naproxen 500 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03663959

Intervention type: PROCEDURE
Intervention: vaginal sacrospinous fixation procedure with dr.Aksakal's desta suture carrier
Description: A right sacrospinous fixation using Dr. Aksakal's Desta suture carrier with two permanent sutures that combined the sacrospinous ligament and vaginal cuff fascia was done. The Desta suture carrier was developed for deep pelvic surgery, and the suture depth can be easily adjusted. After the vaginal hysterectomy, under the vaginal cuff mucosa, we created a tunnel through the spinous process with a straight tool. After passing the rectovaginal pillars, the perirectal space was entered and the ischial spine was palpated. With the help of an index finger placed on the spinous process, we placed two permanent sutures 1.5-2 cm medial to the spinous process on the sacrospinous ligament and iliococcygeus muscle complex using the Desta suture carrier. Next, permanent sutures were combined with the pubocervicovaginal and rectovaginal fascia under the vaginal cuff mucosa.

Intervention type: PROCEDURE
Intervention: Laparoscopic Pectocolpopexy procedure
Description: First, the peritoneal layer above and lateral to the bladder was opened parallel to the round ligament toward the pelvic side wall on the right side. Then, with the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medial to the external iliac vein, the iliopectineal ligament was found . At this point, a segment of approximately 3-4 cm2 was formed, exposing the iliopectineal (Cooper's) ligament. In this area, behind the obliterated umbilical artery, the obturator nerve could be seen, and special care was given not to make contact with the nerve. The same area on the left side was prepared using the same steps. Then, anterior part of the vaginal cuff was prepared for mesh fixation. Bilaterally, the ends of a polypropylene monofilament mesh (1,5x15 cm) were fixed to the iliopectineal ligament with nonabsorbable polypropylene or polyester sutures . The vaginal cuff was elevated to POP-Q level 0-1.
Study: NCT01715259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate: participants with end-stage renal disease
Description: abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate: matched control participants with normal renal function
Description: abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
Study: NCT04650516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 20 minutes treatment in virtual reality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital control
Description: 20 minutes digital control movie on tablet without virtual reality
Study: NCT03341715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavoglurant (AFQ056)
Description: 2-100mg tablets of Mavoglurant will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two matching tablets of placebo will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
Study: NCT01027026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early discharge
Description: The patients are discharged the same day as coronary angiography.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual. No intervention. (Control group)
Description: The patients are admitted and cared as usual in cardiology ward.
Study: NCT01838863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Type AB plasma
Description: The plasma is thawed and administered to subjects in the experimental (plasma) arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid fluid (standard of care for resuscitation)
Description: Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
Study: NCT00179218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplementation
Description: oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplementation
Description: oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: leg press exercise; every other day, 3 days per week, for 6 months
Study: NCT01909817

Intervention type: PROCEDURE
Intervention: Routine coronary angiogram
Study: NCT02832895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial doppler examination
Description: Assessment of frontal bone window for transcranial doppler
Study: NCT06535282

Intervention type: OTHER
Group type: OTHER
Intervention: surgery
Description: Surgical treatment of conductive hearing loss with tinnitus
Study: NCT03526185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab
Description: • Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
Study: NCT03025659

Intervention type: OTHER
Intervention: Pyruvate levels
Description: An additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw (Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 for participants 10kg and above or only at Hour 0, 2, 4, 6, 8, and 12 for infants under 10 kg) to measure the concentration of pyruvate in blood.
Study: NCT00875537

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin oral gel 0.025%
Description: Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin oral gel 0.01%
Description: Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
Study: NCT00854386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liberal fluid administration
Description: patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
Study: NCT00231166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCD122
Study: NCT03796585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immunization Registry Training
Description: Education highlighting practical strategies to improve pharmacies' willingness to adopt the immunization registry and improve their ability to integrate the immunization registry into their pharmacy workflow.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational flyer
Description: Informational flyer with ImmPRINT contact information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational flyer
Description: Informational flyer with ImmPRINT contact information